About the Author
Dr. Nina Patel, MD, FACE
Board-Certified Endocrinologist
Clinical Background
Dr. Nina Patel is a board-certified endocrinologist with over 15 years of clinical experience in diabetes management and metabolic medicine. Her research and clinical practice focus on GLP-1 receptor agonist therapies, including semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro, Zepbound).
As the clinical reviewer for Gluco6 Health, Dr. Patel ensures that all documentation meets the highest standards of medical accuracy and reflects current prescribing guidelines, clinical trial data, and real-world evidence from endocrinology practice.
Editorial Standards
Every article published on Gluco6 Health undergoes a rigorous review process:
- All clinical claims are referenced to peer-reviewed literature or FDA prescribing information
- Dosage information is verified against current manufacturer guidelines
- Side effect frequencies are sourced from phase III clinical trial data
- Content is reviewed and updated on a monthly cycle to reflect new evidence
- Drug interaction information is cross-referenced with multiple pharmacological databases
Disclaimer
The information on Gluco6 Health is intended for educational purposes only and should not be considered medical advice. Always consult with a qualified healthcare provider before starting, stopping, or modifying any medication regimen. Individual responses to GLP-1 medications vary, and treatment decisions should be made in partnership with your prescribing physician.